No Data
Anavex Reports Phase III Results for Alzheimer's Drug Targeting SIGMAR1 Gene
Anavex Life Sciences Shares Are Trading Higher After the Company Announced New Data From the Phase IIb/III Study Showing That Blarcamesine, Once Daily Orally, Demonstrates Pre-specified Clinical Efficacy Through Upstream SIGMAR1 Activation.
12 Health Care Stocks Moving In Thursday's Intraday Session
JonesTrading Maintains Anavex Life Sciences(AVXL.US) With Buy Rating, Maintains Target Price $15
Anavex Life Sciences Is Maintained at Buy by EF Hutton
Anavex Gains as Lead Asset Slows Alzheimer's Disease Progression by a Third
No Data
No Data
Rockhoundj : $Cardio Diagnostics (CDIO.US)$
Is looking strong
Take a
Stock_Drift OP Rockhoundj : Agreed. Could be a good AH’s run!!?
Stock_Drift OP Rockhoundj : Let’s Go!!! $Cardio Diagnostics (CDIO.US)$